AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bray, G. A.
Right arrow Articles by Chopra, I. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bray, G. A.
Right arrow Articles by Chopra, I. J.
Agricola
Right arrow Articles by Bray, G. A.
Right arrow Articles by Chopra, I. J.

American Journal of Clinical Nutrition, Vol 26, 715-721, Copyright © 1973 by The American Society for Clinical Nutrition, Inc.

Effect of triiodothyronine on some metabolic responses of obese patients

George A. Bray 1, Kenneth E. W. Melvin 1, and Inder J. Chopra 1

1 From the Departments of Medicine, Harbor General Hospital, Torrance, California and the University of California School of Medicine, Los Angeles, and the Departments of Medicine, New England Medical Center Hospitals and Tufts University School of Medicine, Boston, Massachusetts

We have examined some responses of obese patients to triiodothyronine (T3) in three separate studies. Subjects treated with T3, 150 µg/day, showed a rise in oxygen uptake and the catabolism of fat and protein. Approximately 75% of the extra oxygen consumed could be accounted for by catabolism of fat. Yet breakdown of lean body mass produced nearly 80% of the weight loss. On an outpatient basis, 12 grossly obese patients were treated in a double-blind, randomized trial with either 225 µg triiodothyronine or with identically appearing placebo tablets for 1 month followed by a 2nd month of the opposite therapy. During the period on T3, there was an average rise of six beats/min in heart rate and a significant loss of weight. Radioactive iodine uptake and serum thyroxine were suppressed during T3 treatment, and the serum T3 concentrations were distinctly above normal. However, 6 of the 12 patients did not demonstrate clinical symptoms by which the period of treatment with T3 could be identified. As all patients had objective physiological changes, the use of clinical symptomatic responses may be an inadequate technique for evaluating the effects of thyroid hormone therapy.




This article has been cited by other articles:


Home page
 J EndocrinolHome page
R. L. Araujo, B. M. de Andrade, A. S. P. de Figueiredo, M. L. da Silva, M. P. Marassi, V. dos Santos Pereira, E. Bouskela, and D. P Carvalho
Low replacement doses of thyroxine during food restriction restores type 1 deiodinase activity in rats and promotes body protein loss
J. Endocrinol., July 1, 2008; 198(1): 119 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
T. E. Sheehan, P. A. Kumar, and D. A. Hood
Tissue-specific regulation of cytochrome c oxidase subunit expression by thyroid hormone
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E968 - E974.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. A. Bray and F. L. Greenway
Current and Potential Drugs for Treatment of Obesity
Endocr. Rev., December 1, 1999; 20(6): 805 - 875.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Ramirez, L. E. Braverman, B. White, and C. H. Emerson
Recombinant Human Thyrotropin Is a Potent Stimulator of Thyroid Function in Normal Subjects
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2836 - 2839.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1973 by The American Society for Nutrition